Results from pivotal trials consistently showed treatment with brexanolone injection provided significant and rapid reduction in depressive symptoms within days of initiating therapy Treatment response was durable over the follow-up period, across three placebo-controlled trials ZULRESSO™

Conditional acceptance granted by U.S. Food and Drug Administration ( FDA ) for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone Continuing to execute commercial build and launch readiness for ZULRESSO™ (brexanolone injection) in postpartum depression ahead of PDUFA

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018 , the Compensation Committee of Sage’s

Collaboration intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the world Collaboration supports Shionogi’s vision of creating a more vigorous society by exploring the potential to provide relief

Expedited SAGE-217 development plan to support potential NDA submission for MDD and PPD Previously completed placebo-controlled study in MDD considered as pivotal; initiation of one additional Phase 3 pivotal trial anticipated in 2H of 2018 Ongoing study in PPD designated as pivotal; results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39 th Annual

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018 , the Compensation Committee of Sage’s